Browse the evidence

Consumption of extra-virgin olive oil (EVOO) as part of a Mediterranean diet reduces systolic and diastolic blood pressure in individuals with high cardiovascular risk.

Replace other fats with extra-virgin olive oil in your daily cooking and dressings. Aim for 10-50 mL per day as part of a Mediterranean-style diet. Do not rely on olive oil capsules, as they do not offer the same cardiovascular benefits.

Higher TyG-BMI values are positively and linearly associated with increased risk of cardiovascular disease in individuals with Cardiovascular-Kidney-Metabolic (CKM) syndrome stages 0-3.

If you have metabolic risk factors or early kidney/heart issues, monitoring your Triglyceride-Glucose BMI (TyG-BMI) is a valuable tool for predicting heart disease risk. This index combines your body mass with blood sugar and fat levels to assess insulin resistance. Keeping this index low through lifestyle management (diet and exercise) is critical for preventing cardiovascular events, especially if you are over 45.

Local thyroid hormone activation in skeletal muscle via D2 drives a shift from slow-twitch (Type I) to fast-twitch (Type II) fibers, increasing energy expenditure and influencing insulin sensitivity.

Skeletal muscle uses local thyroid hormone activation to adjust its metabolic profile. Higher local T3 levels promote fast-twitch fibers and increase energy expenditure through heat production and glucose uptake. This suggests that muscle-specific thyroid regulation plays a key role in metabolic flexibility and insulin sensitivity.

Higher baseline PFAS levels (specifically PFOS and PFNA) are associated with a greater decline in Resting Metabolic Rate (RMR) during the initial weight loss phase and a blunted increase in RMR during the weight regain phase.

This finding explains why some people struggle to keep weight off despite eating less: their metabolism doesn't 'bounce back' as it should. High levels of environmental chemicals (PFAS) may blunt this metabolic recovery. To counteract this, prioritize resistance training to build metabolically active tissue, as this may help override the blunted RMR response caused by environmental factors.

Hyperinsulinemia is a causal driver of obesity and lipid accumulation, rather than merely a compensatory response to insulin resistance or caloric surplus.

If you struggle with obesity, high insulin levels may be driving your fat storage, not just a result of it. Strategies that lower insulin (like low-carb diets, time-restricted feeding, or exercise) may be more effective for weight loss than calorie restriction alone, as they address the hormonal driver of lipid accumulation.

Type 2 diabetes mellitus is associated with a significantly higher prevalence of sarcopenia (defined by low lean mass and muscle weakness) compared to healthy controls, independent of diabetes duration or glycemic control.

If you have Type 2 Diabetes, you are at significantly higher risk for muscle loss than someone without diabetes, even if your blood sugar is well-controlled. This loss is not just 'aging'; it is a specific complication of the disease. You should ask your doctor to check your muscle strength (e.g., handgrip) and lean mass, as early detection allows for rehabilitation to restore physical capacity.

Liraglutide (3.0 mg) produces significant weight loss (-5.4% placebo-subtracted) and improves cardiovascular risk factors, but has a high discontinuation rate due to gastrointestinal side effects.

Liraglutide is a daily injection that helps lose about 5% more weight than placebo and improves heart health markers. However, it often causes nausea and vomiting, leading many patients to stop taking it.

For very short bouts of physical activity (less than 1 minute), a minimum proportion of vigorous intensity (at least 12-15%) is required to significantly reduce the risk of Major Adverse Cardiovascular Events (MACE), though all-cause mortality benefits may appear at lower vigorous thresholds.

If you can only manage very short bursts of activity (under a minute), make sure they include some vigorous effort, like running up stairs quickly or walking very fast. This high-intensity component is crucial for protecting your heart when the duration is minimal.

Obesity-related sub-acute chronic inflammation acts as a pathologic mediator for both type 2 diabetes and atherosclerotic cardiovascular disease, with inflammatory markers like CRP predicting risk independently of weight.

If you have obesity or type 2 diabetes, your body's chronic low-grade inflammation is likely driving your risk for heart disease and worsening insulin resistance. While weight loss reduces this inflammation, specific anti-inflammatory strategies (like certain diabetes or cardiovascular drugs) may offer additional protection. Discuss with your doctor whether your current regimen addresses inflammatory risk, not just blood sugar or weight.

Acute vigorous submaximal exercise (67% VO2max for 60 minutes) significantly increases circulating GDF15 levels in humans, with levels continuing to rise during the recovery period.

Performing vigorous exercise (around 67% of your max capacity) for an hour triggers a significant rise in GDF15, a hormone linked to appetite suppression and energy balance. This rise continues for at least two hours after you stop exercising. While this doesn't mean your muscles are releasing the hormone directly, the systemic effect is real and substantial.

Night shift work and rapid time-zone changes disrupt circadian rhythms, leading to increased morbidity, mortality, and cognitive impairment.

If you work night shifts, use bright light exposure during your shift and wear blue-light-blocking glasses on your commute home. Prioritize a dark, quiet sleeping environment during the day. Be aware that long-term night work increases health risks, so monitor your health closely.

Insulin resistance (IR) and hyperinsulinemia are key etiological components of PCOS that drive excessive ovarian androgen production, leading to reproductive dysfunction, independent of but amplified by obesity.

Understanding that insulin resistance drives PCOS symptoms is crucial. Treating insulin resistance through diet and lifestyle can help reduce androgen levels and restore ovulation, even without significant weight loss.

Regular aerobic exercise increases HDL cholesterol levels and enhances Reverse Cholesterol Transport (RCT) efficiency by upregulating key receptors (ABCA1, ABCG1, SR-B1) and enzymes (LCAT, CETP).

Engage in regular aerobic exercise, such as walking or cycling. You do not need extreme intensity; even moderate activities like walking 10,000 steps three times a week can improve your HDL cholesterol and overall lipid profile. Consistency is key, and combining aerobic with resistance training may offer additional benefits.

Synthesis of the mitochondrial phospholipid cardiolipin (CL) in brown and beige fat is essential for systemic energy homeostasis, insulin sensitivity, and metabolic flexibility.

Maintaining healthy brown and beige fat function appears crucial for metabolic health. This involves exposure to cold temperatures which naturally upregulates cardiolipin synthesis. While you cannot directly 'dose' cardiolipin, supporting thermogenic capacity through cold exposure may help maintain insulin sensitivity and metabolic flexibility, especially if you have reduced brown fat activity.

Empagliflozin (10 mg/day) significantly reduces liver fibrosis (measured by liver stiffness measurement) in patients with Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease compared to placebo, and reduces liver stiffness more effectively than pioglitazone.

If you have Type 2 Diabetes and fatty liver disease, ask your doctor about empagliflozin (10 mg daily). This study shows it can significantly reduce liver stiffness (a sign of scarring/fibrosis) better than the alternative drug pioglitazone, and better than a placebo. It also helps reduce body weight and visceral fat. Ensure you maintain moderate physical activity and follow dietary advice as part of your treatment.

GLP-1 receptor agonists and SGLT2 inhibitors show promising benefits for NAFLD/NASH patients, particularly by addressing underlying metabolic dysfunction, though specific histological resolution data is still emerging.

If lifestyle changes aren't enough to manage your fatty liver, ask your doctor about GLP-1 agonists (like semaglutide) or SGLT2 inhibitors (like empagliflozin). These diabetes/obesity drugs have shown promise in improving liver health by targeting the underlying metabolic issues.

Assessment of metabolic risk factors is critical in patients with NAFLD because advanced liver fibrosis correlates with metabolic comorbidities, and early identification of these factors prevents cardiovascular and liver-related mortality.

If you have NAFLD, focus on managing your metabolic health (blood sugar, blood pressure, weight) even if your liver enzymes look normal. This is the most effective way to protect your heart and liver from serious damage.

Higher percentages of REM and deep sleep are associated with a reduced incidence of atrial fibrillation, while higher light sleep percentages are associated with increased odds of atrial fibrillation.

Prioritize sleep quality that promotes REM and deep sleep. While total duration is important, the composition of your sleep matters for heart health. Consistent sleep schedules and avoiding alcohol before bed may help increase deep and REM sleep, thereby reducing atrial fibrillation risk.

Average daily sleep duration exhibits a J-shaped association with hypertension, major depressive disorder, and generalized anxiety disorder, where both short (5h) and long (10h) durations increase risk compared to the median (6.8h).

Aim for approximately 7 hours of sleep per night. Both sleeping significantly less (5 hours) or significantly more (10 hours) is associated with higher risks of hypertension, depression, and anxiety. Use your wearable to track your average daily sleep duration and adjust your schedule to stay within the moderate range.

GLP-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events (MACE) in type 2 diabetes patients through pleiotropic mechanisms including blood pressure reduction, improved endothelial function, and anti-inflammatory effects, independent of weight loss.

If you have type 2 diabetes and are at risk for heart problems, GLP-1 receptor agonists (like semaglutide or liraglutide) offer heart protection beyond just lowering blood sugar. They work by improving blood vessel function and lowering blood pressure. While they are injections that can cause stomach upset, the cardiovascular benefits are significant and often independent of weight loss.

A low-protein/high-carbohydrate (LPHC) diet or specific restriction of methionine and branched-chain amino acids (BCAAs) extends longevity and improves metabolic health in model organisms and middle-aged humans by suppressing mTORC1 and GH/IGF-1 signaling while promoting autophagy and FGF21 production.

Focus on the source and balance of protein rather than just total grams. Prioritize plant-based proteins and consider reducing methionine-rich animal proteins (like red meat) if you are middle-aged, as this may support longevity pathways. However, ensure adequate protein intake in older age to prevent frailty.

Testosterone treatment significantly reduces depressive symptoms in men compared to placebo, with efficacy dependent on dosage and baseline symptom homogeneity.

If you are a man experiencing depressive symptoms, testosterone therapy may offer a clinically relevant reduction in symptoms, particularly if your symptoms are consistent (low variability) and you are prescribed a higher dosage (over 500mg/week). This benefit appears regardless of whether you are clinically hypogonadal. Consult a physician to evaluate if this adjunct therapy is appropriate for your specific symptom profile.

Semaglutide at its maximum tolerated dose (MTD) is associated with the highest odds of treatment discontinuation due to adverse events among all tested regimens, including tirzepatide MTD.

If you choose semaglutide at its maximum dose, be aware that you have the highest statistical risk of stopping the medication due to side effects compared to other options in this study. Monitor your tolerance closely and communicate with your provider immediately if side effects become unmanageable.

Tirzepatide demonstrates cardiovascular safety, with hazard ratios for major adverse cardiovascular events (MACE) remaining below 1.3 compared to pooled comparators, indicating no increased cardiovascular risk.

For patients with heart disease or high risk factors, Tirzepatide has been shown to be safe regarding cardiovascular events. It does not increase the risk of heart attack, stroke, or cardiovascular death compared to standard treatments. This makes it a viable option for those who need effective diabetes management without compromising heart health.